There is a growing clinical evidence that suggests the presence of a molecular crosstalk between ER and HER2 pathways [49,50], indicating ER+/HER2+ breast cancers as a distinct breast cancer subtype that may require a specific approach in treatment [51]. The gene discussed is ERBB2; the disease is breast cancer.